Iambic Therapeutics, Inc. (IAM) income statement
IAMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 19, 2026
$13.11−1.15 (-8.06%)
Close on Nov 20, 2026Market cap $60.83MP/E –Yield –
Iambic Therapeutics, Inc. financial ratios
See a number that looks wrong?